{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:06:17Z","timestamp":1783609577741,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T00:00:00Z","timestamp":1657324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T00:00:00Z","timestamp":1657324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Cheetah Cell Therapeutics"},{"name":"Singapore Ministry of Health\u2019s National Medical Research Council","award":["NMRC\/OFLCG\/003\/2018; MOH-000465-01"],"award-info":[{"award-number":["NMRC\/OFLCG\/003\/2018; MOH-000465-01"]}]},{"DOI":"10.13039\/501100001348","name":"Agency for Science, Technology and Research","doi-asserted-by":"publisher","award":["IAF-PP:H19\/01\/a0\/022"],"award-info":[{"award-number":["IAF-PP:H19\/01\/a0\/022"]}],"id":[{"id":"10.13039\/501100001348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00262-022-03247-9","type":"journal-article","created":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T08:03:07Z","timestamp":1657353787000},"page":"223-234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Dual CAR-T cells to treat cancers co-expressing NKG2D and PD1 ligands in xenograft models of peritoneal metastasis"],"prefix":"10.1007","volume":"72","author":[{"given":"Guangyi","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Yang","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan C. K.","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicheng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,9]]},"reference":[{"issue":"1","key":"3247_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41572-021-00326-6","volume":"7","author":"D Cortes-Guiral","year":"2021","unstructured":"Cortes-Guiral D, Hubner M, Alyami M, Bhatt A, Ceelen W, Glehen O et al (2021) Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers 7(1):91","journal-title":"Nat Rev Dis Primers"},{"key":"3247_CR2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.pharmthera.2017.12.002","volume":"185","author":"A Krishnamurthy","year":"2018","unstructured":"Krishnamurthy A, Jimeno A (2018) Bispecific antibodies for cancer therapy: a review. Pharmacol Ther 185:122\u2013134","journal-title":"Pharmacol Ther"},{"issue":"12","key":"3247_CR3","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1080\/14712598.2020.1803273","volume":"20","author":"M Lazarova","year":"2020","unstructured":"Lazarova M, Wels WS, Steinle A (2020) Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D\/NKG2D-ligand system. Expert Opin Biol Ther 20(12):1491\u20131501","journal-title":"Expert Opin Biol Ther"},{"key":"3247_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.713158","volume":"12","author":"MB Fuertes","year":"2021","unstructured":"Fuertes MB, Domaica CI, Zwirner NW (2021) Leveraging NKG2D ligands in immuno-oncology. Front Immunol 12:713158","journal-title":"Front Immunol"},{"issue":"1","key":"3247_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3390\/ijms19010177","volume":"19","author":"H Ding","year":"2018","unstructured":"Ding H, Yang X, Wei Y (2018) Fusion proteins of NKG2D\/NKG2DL in cancer immunotherapy. Int J Mol Sci 19(1):177","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3247_CR6","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/PPO.0000000000000029","volume":"20","author":"CL Sentman","year":"2014","unstructured":"Sentman CL, Meehan KR (2014) NKG2D CARs as cell therapy for cancer. Cancer J 20(2):156\u2013159","journal-title":"Cancer J"},{"issue":"18","key":"3247_CR7","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2217\/fon-2017-0102","volume":"13","author":"B Demoulin","year":"2017","unstructured":"Demoulin B, Cook WJ, Murad J, Graber DJ, Sentman ML, Lonez C et al (2017) Exploiting natural killer group 2D receptors for CAR T-cell therapy. Future Oncol 13(18):1593\u20131605","journal-title":"Future Oncol"},{"issue":"3","key":"3247_CR8","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1158\/2326-6066.CIR-18-0572","volume":"7","author":"R Parihar","year":"2019","unstructured":"Parihar R, Rivas C, Huynh M, Omer B, Lapteva N, Metelitsa LS et al (2019) NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors. Cancer Immunol Res 7(3):363\u2013375","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"3247_CR9","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.ymthe.2019.03.011","volume":"27","author":"L Xiao","year":"2019","unstructured":"Xiao L, Cen D, Gan H, Sun Y, Huang N, Xiong H et al (2019) Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients. Mol Ther 27(6):1114\u20131125","journal-title":"Mol Ther"},{"issue":"1","key":"3247_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/cei.13478","volume":"202","author":"J Obajdin","year":"2020","unstructured":"Obajdin J, Davies DM, Maher J (2020) Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer. Clin Exp Immunol 202(1):11\u201327","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"3247_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ymthe.2020.08.016","volume":"29","author":"YY Ng","year":"2021","unstructured":"Ng YY, Tay JCK, Li Z, Wang J, Zhu J, Wang S (2021) T cells expressing NKG2D CAR with a DAP12 signaling domain stimulate lower cytokine production while effective in tumor eradication. Mol Ther 29(1):75\u201385","journal-title":"Mol Ther"},{"key":"3247_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.omtm.2021.02.023","volume":"21","author":"JCK Tay","year":"2021","unstructured":"Tay JCK, Wang J, Du Z, Ng YY, Li Z, Ren Y et al (2021) Manufacturing NKG2D CAR-T cells with piggyBac transposon vectors and K562 artificial antigen-presenting cells. Mol Ther Methods Clin Dev 21:107\u2013120","journal-title":"Mol Ther Methods Clin Dev"},{"key":"3247_CR13","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.omtm.2021.10.014","volume":"23","author":"Z Du","year":"2021","unstructured":"Du Z, Ng YY, Zha S, Wang S (2021) piggyBac system to co-express NKG2D CAR and IL-15 to augment the in vivo persistence and anti-AML activity of human peripheral blood NK cells. Mol Ther Methods Clin Dev 23:582\u2013596","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"10","key":"3247_CR14","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/mt.2015.119","volume":"23","author":"H VanSeggelen","year":"2015","unstructured":"VanSeggelen H, Hammill JA, Dvorkin-Gheva A, Tantalo DG, Kwiecien JM, Denisova GF et al (2015) T cells engineered with chimeric antigen receptors targeting NKG2D ligands display lethal toxicity in mice. Mol Ther 23(10):1600\u20131610","journal-title":"Mol Ther"},{"key":"3247_CR15","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3389\/fimmu.2020.00326","volume":"11","author":"LJB Brandt","year":"2020","unstructured":"Brandt LJB, Barnkob MB, Michaels YS, Heiselberg J, Barington T (2020) Emerging approaches for regulation and control of CAR T cells: a mini review. Front Immunol 11:326","journal-title":"Front Immunol"},{"key":"3247_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2021.101480","volume":"52","author":"KE Pauken","year":"2021","unstructured":"Pauken KE, Torchia JA, Chaudhri A, Sharpe AH, Freeman GJ (2021) Emerging concepts in PD-1 checkpoint biology. Semin Immunol 52:101480","journal-title":"Semin Immunol"},{"issue":"6","key":"3247_CR17","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","volume":"76","author":"X Liu","year":"2016","unstructured":"Liu X, Ranganathan R, Jiang S, Fang C, Sun J, Kim S et al (2016) A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Res 76(6):1578\u20131590","journal-title":"Cancer Res"},{"issue":"13","key":"3247_CR18","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1158\/0008-5472.CAN-16-1922","volume":"77","author":"R Schlenker","year":"2017","unstructured":"Schlenker R, Olguin-Contreras LF, Leisegang M, Schnappinger J, Disovic A, Ruhland S et al (2017) Chimeric PD-1:28 receptor upgrades low-avidity T cells and restores effector function of tumor-infiltrating lymphocytes for adoptive cell therapy. Cancer Res 77(13):3577\u20133590","journal-title":"Cancer Res"},{"issue":"16","key":"3247_CR19","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.2217\/imt-2017-0103","volume":"9","author":"JC Tay","year":"2017","unstructured":"Tay JC, Zha S, Wang S (2017) Chimeric switch receptor: switching for improved adoptive T-cell therapy against cancers. Immunotherapy 9(16):1339\u20131349","journal-title":"Immunotherapy"},{"issue":"9","key":"3247_CR20","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ et al (2018) Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol 36(9):847\u2013856","journal-title":"Nat Biotechnol"},{"issue":"1","key":"3247_CR21","doi-asserted-by":"publisher","first-page":"1901434","DOI":"10.1080\/2162402X.2021.1901434","volume":"10","author":"C Chen","year":"2021","unstructured":"Chen C, Gu YM, Zhang F, Zhang ZC, Zhang YT, He YD et al (2021) Construction of PD1\/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer. Oncoimmunology 10(1):1901434","journal-title":"Oncoimmunology"},{"issue":"2","key":"3247_CR22","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/1078-0432.CCR-20-1457","volume":"27","author":"H Liu","year":"2021","unstructured":"Liu H, Lei W, Zhang C, Yang C, Wei J, Guo Q et al (2021) CD19-specific CAR T cells that express a PD-1\/CD28 chimeric switch-receptor are effective in patients with PD-L1-positive B-cell lymphoma. Clin Cancer Res 27(2):473\u2013484","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3247_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13045-021-01044-y","volume":"14","author":"Y Liang","year":"2021","unstructured":"Liang Y, Liu H, Lu Z, Lei W, Zhang C, Li P et al (2021) CD19 CAR-T expressing PD-1\/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies. J Hematol Oncol 14(1):26","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3247_CR24","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","volume":"25","author":"J Feucht","year":"2019","unstructured":"Feucht J, Sun J, Eyquem J, Ho YJ, Zhao Z, Leibold J et al (2019) Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat Med 25(1):82\u201388","journal-title":"Nat Med"},{"issue":"12","key":"3247_CR25","doi-asserted-by":"publisher","first-page":"4674","DOI":"10.4049\/jimmunol.1600769","volume":"197","author":"ML Sentman","year":"2016","unstructured":"Sentman ML, Murad JM, Cook WJ, Wu MR, Reder J, Baumeister SH et al (2016) Mechanisms of acute toxicity in NKG2D chimeric antigen receptor T cell-treated mice. J Immunol 197(12):4674\u20134685","journal-title":"J Immunol"},{"key":"3247_CR26","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1200\/JCO.2021.39.3_suppl.74","volume":"39","author":"JD Hans Prenen","year":"2021","unstructured":"Hans Prenen JD et al (2021) Updated data from alloSHRINK phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC. ASCO GI J Clin Oncol 39:74","journal-title":"ASCO GI J Clin Oncol"},{"key":"3247_CR27","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.3389\/fimmu.2018.02040","volume":"9","author":"D Schmiedel","year":"2018","unstructured":"Schmiedel D, Mandelboim O (2018) NKG2D ligands-critical targets for cancer immune escape and therapy. Front Immunol 9:2040","journal-title":"Front Immunol"},{"issue":"10","key":"3247_CR28","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1346766","volume":"6","author":"A Lopez-Soto","year":"2017","unstructured":"Lopez-Soto A, Gonzalez S, Galluzzi L (2017) Soluble NKG2D ligands limit the efficacy of immune checkpoint blockade. Oncoimmunology 6(10):e1346766","journal-title":"Oncoimmunology"},{"issue":"5","key":"3247_CR29","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser R, Cherkassky L, Chintala N, Adusumilli PS (2019) Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell 36(5):471\u2013482","journal-title":"Cancer Cell"},{"issue":"3","key":"3247_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrclinonc.2015.209","volume":"13","author":"MJ Smyth","year":"2016","unstructured":"Smyth MJ, Ngiow SF, Ribas A, Teng MW (2016) Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol 13(3):143\u2013158","journal-title":"Nat Rev Clin Oncol"},{"issue":"47","key":"3247_CR31","doi-asserted-by":"publisher","first-page":"E6506","DOI":"10.1073\/pnas.1519623112","volume":"112","author":"RL Maute","year":"2015","unstructured":"Maute RL, Gordon SR, Mayer AT, McCracken MN, Natarajan A, Ring NG et al (2015) Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci USA 112(47):E6506\u2013E6514","journal-title":"Proc Natl Acad Sci USA"},{"issue":"17","key":"3247_CR32","doi-asserted-by":"publisher","first-page":"11771","DOI":"10.1074\/jbc.M112.448126","volume":"288","author":"X Cheng","year":"2013","unstructured":"Cheng X, Veverka V, Radhakrishnan A, Waters LC, Muskett FW, Morgan SH et al (2013) Structure and interactions of the human programmed cell death 1 receptor. J Biol Chem 288(17):11771\u201311785","journal-title":"J Biol Chem"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03247-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-022-03247-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03247-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T12:06:02Z","timestamp":1672833962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-022-03247-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,9]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["3247"],"URL":"https:\/\/doi.org\/10.1007\/s00262-022-03247-9","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,9]]},"assertion":[{"value":"12 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors Shu Wang, Yu Yang Ng, Johan CK Tay have filed patent applications related to CAR technology and could potentially receive licensing royalties in future. Lin Xiao is employee of Cheetah Cell Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}